SecBot SecBot
SECBOTREPLAY Home › Report › BBIO

BBIO · BridgeBio Pharma presented positive interim Phase 3 FORTIFY trial…

BridgeBio Pharma, Inc. · PRESS-RELEASE filed Mar 11, 2026 at 14:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 11, 2026 at 14:00 ET

BridgeBio Pharma presented positive interim Phase 3 FORTIFY trial results for BBP-418, an oral therapy for LGMD2I/R9, showing rapid and sustained efficacy across key endpoints including ambulation and biomarker improvements, with a safety profile comparable to placebo. Based on these results, the company plans to submit an NDA to the FDA in the first half of 2026, with a potential U.S. launch in late 2026 or early 2027. If approved, BBP-418 would be the first therapy for LGMD2I/R9 and potentially the first for any limb-girdle muscular dystrophy (LGMD) subtype.

  • Positive interim Phase 3 FORTIFY trial results show BBP-418 improved ambulation (31-second advantage on 100MTT at 12 months vs. placebo) and reduced serum creatine kinase, with effects seen as early as 3 months.
  • BBP-418 demonstrated consistent benefit across all prespecified subgroups (genotype, age, FVC) and achieved normalization of CK in 38.3% of patients after 12 months.
  • Safety profile was favorable, with no treatment-related serious adverse events and no new safety signals.
  • BridgeBio plans to submit an NDA to the FDA in the first half of 2026, with a potential U.S. launch in late 2026/early 2027.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access